Antihypertensive Drugs Market is expected to reach $28,797 million by 2026

The antihypertensive drugs industry was pegged at $22.56 billion in 2018, and is estimated to reach $28.79 billion by 2026, growing at a CAGR of 3.1% from 2019 to 2026

Request a Sample Copy of the Research Report: @ https://www.alliedmarketresearch.com/request-sample/436

Antihypertensive Drugs Market Research has offered exhaustive analysis of Manufacturers, Suppliers, Regions, Type and Application, Forecast to 2027. also provides essential study on the current status of the market, cover market size with respect to valuation as sales volume and providing a precise prediction of the market scenario over the forecast period from 2020 to 2027.

The report provides revenue forecast with sales, sales growth rate, and revenue growth rate forecasts of the global Antihypertensive Drugs Market. The forecasts are also provided with respect to the product, application, and regional segments of the market. The forecasts are provided to understand the outlook and prospects for the market.

Get detailed COVID-19 impact analysis on the Antihypertensive Drugs Market

https://www.alliedmarketresearch.com/request-for-customization/436?reqfor=covid

Major market players

Boehringer Ingelheim GmbH
Johnson and Johnson
Merck KGaA
Pfizer, Inc.
Bayer AG
AstraZeneca plc
Takeda Pharmaceutical Co., Ltd.
Sanofi S.A.
Daiichi Sankyo Company
Novartis International AG
The global antihypertensive drugs market size is categorized on the basis of therapeutic class, distribution channel, and region. Based on drug class, the market is divided into diuretics, ACE inhibitors, calcium channel blockers, vasodilators, beta-adrenergic blockers, and others. The calcium channel blockers segment held the largest share in 2018, contributing to more than one-fourth of the global antihypertensive drugs market. However, the ACE inhibitors segment is projected to manifest the fastest CAGR of 4.7% during the forecast period.

Based on distribution channel, the market is categorized into retail pharmacy, hospital pharmacy, and e-commerce. The e-commerce websites and online drug stores segment is expected to register the fastest CAGR of 4.2% through 2026. On the other hand, the hospital pharmacy segment accounted for the highest share in 2018, contributing to more than half of the global antihypertensive drugs market.

The ACE inhibitors segment to manifest fastest CAGR through 2026

The ACE inhibitors segment is projected to register the fastest CAGR of 4.7% during the forecast period, owing to the positive impact these drugs have on the overall health and extensive use of ACE inhibitors in various types of hypertension. However, the calcium channel blockers segment held the largest share in 2018, contributing to more than one-fourth of the global antihypertensive drugs market, owing to lesser side effects exhibited by these drugs as compared to the other type of antihypertensive drugs.

The hospital pharmacy segment held the largest share

The hospital pharmacy segment dominated the market in 2018, accounting for more than half of the global antihypertensive drugs market, owing to increase in the number of hospitalized NASH patients, surge in number of hospital pharmacies, improvement in structure of hospital pharmacies in the emerging countries such as China and India. However, the e-commerce websites & online drug stores segment is projected to register the fastest CAGR of 4.2% during the study period, due to surge in preference for online purchasing of drugs over the traditional methods, rise in the number of Internet users, and increase in awareness of online pharmacy.

North America dominated the market

The global antihypertensive drugs market across North America held the largest share in 2018, accounting for more than one-third of the market, owing to the availability of the antihypertensive drugs and rise in prevalence of hypertension due to surge in geriatric population in the region. However, the market across the Asia-Pacific region is anticipated to portray the fastest CAGR of 4.2% during the forecast period, owing to surge in awareness related to use of antihypertensive drugs and the presence of active key players in the region.

Read More @ https://www.alliedmarketresearch.com/antihypertensives-market

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): 1-800-792-5285, 1-503-894-6022, 1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.